GlassScriptPhysician profile
Julie E Schweitzer
NPI 1215479134
$5,628.59
in general payments reported to CMS, 2019-2025
31 companies · $549 in 2025
The $549 reported for 2025 was more than what 88% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,710 · 2022: $1,413 · 2023: $1,460 · 2024: $497 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,164.46 | 2021-2025 | |
| Abbvie INC. | $1,098.74 | 2021-2025 | |
| Avion Pharmaceuticals | $723.79 | 2021-2023 | Balcoltra |
| Evofem Biosciences, INC. | $550.89 | 2021-2025 | Phexxi, Solosec, Phexx |
| Novo Nordisk INC | $201.04 | 2021-2024 | Wegovy |
| Exeltis, USA INC. | $146.53 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $145.99 | 2021-2023 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $142.21 | 2021-2022 | |
| Pfizer INC. | $141.24 | 2023-2025 | |
| Therapeuticsmd, INC. | $122.21 | 2021-2022 | |
| Myovant Sciences INC. | $115.43 | 2021-2022 | |
| Sage Therapeutics, LLC | $105.46 | 2021-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $90.92 | 2021-2024 | |
| Astellas Pharma US INC | $89.44 | 2021-2023 | Veozah |
| Currax Pharmaceuticals LLC | $84.68 | 2021-2024 | Contrave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $84.19 | 2021 | |
| Dexcom, INC. | $78.82 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $71.65 | 2021-2023 | Third Wave, Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $71.61 | 2021-2023 | Gardasil 9 |
| Optumhealth Care Solutions, LLC | $68.05 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Sumitomo Pharma America, INC. | $58.67 | 2023-2024 | Myfembree |
| Organon LLC | $48.42 | 2021-2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $43.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.92 | 2022 | |
| Aspira Women'S Health INC | $41.88 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $20.48 | 2025 | Qelbree |
| Allergan, INC. | $19.84 | 2021 | |
| Millicent US INC | $17.13 | 2025 | Intrarosa |
| Minerva Surgical, INC | $14.83 | 2023 | |
| Virtus Pharmaceuticals LLC | $13.13 | 2021 | |
| Impel Pharmaceuticals INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Schweitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.